6533b872fe1ef96bd12d3a4e

RESEARCH PRODUCT

Diabetes and COVID-19: A Tale of 2 Pandemics.

Manfredi RizzoManfredi RizzoWael Al MahmeedAli A. RizviAli A. RizviAndrei Janez

subject

Pharmacology2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)diabetesbusiness.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19Review Articledapagliflozinmedicine.diseaseVirologyDARE-19Diabetes mellitusPandemicmedicineDiabetes MellitusHumansSGLT2iCardiology and Cardiovascular MedicinebusinessPandemicsHumans Pandemics SARS-CoV-2 COVID-19 Diabetes Mellitus

description

Abstract: Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patients With COVID-19), an ongoing clinical trial, is designed to investigate the impact of dapagliflozin on COVID-19 progression. This article discusses the potential favorable impact of dapagliflozin on COVID-19 and its complications.

10.1097/fjc.0000000000001047https://pubmed.ncbi.nlm.nih.gov/34001719